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Summary

Dogs are sometimes referred to as “man’s best friend” and with the increase in urbanization and lifestyle
changes, dogs are seen by their owners as family members. Society expresses specific concerns about
the experimental use of dogs, as they are sometimes perceived to have a special status for humans. This
may appear somewhat conflicting with the idea that the intrinsic value of all animals is the same, and that
also several other animal species are used in biomedical research and toxicology. This aspect and many
others are discussed in an introductory chapter dealing with ethical considerations on the use of dogs
as laboratory animals. The report gives an overview on the use of dogs in biomedical research, safety
assessment and the drug developmental process and reflects the discussion on the use of dogs as second
(non-rodent)species in toxicity testing. Approximately 20,000 dogs are used in scientific procedures in
Europe every year, and their distinct genetic, physiological and behavioral characteristics may support
their use as models for e.g. behavioral analysis and genetic research. Advances in the 3Rs (Replacement,
Reduction and Refinement of experiments using dogs) are described, potential opportunities are
discussed and recommendations for further progress in this area are made.
Keywords: dog use, animal welfare, moral dilemma, second species paradigm, 3Rs
1 Introduction

The workshop on “Critical Evaluation of the Use of Dogs in
Biomedical Research and Testing” hosted by the Centre for Alternatives to Animal Testing (CAAT-Europe) and the transatlantic think tank for toxicology (t 4) took place on June 21-23, 2011
in Budapest, Hungary, and was sponsored by the DoerenkampZbinden Foundation (DZF). Participants from industry, animal
welfare organizations, the regulatory arena and academia came
together to discuss the current use of dogs, the regulatory background, ethical issues, and opportunities to replace, reduce and
refine the use of dogs in biomedical research and testing. This

report reflects the presentations given by the participants, some
background information, and the discussions and recommendations of the workshop. It is not a consensus report, but shows
the spectrum of views. Participants took part in the workshop
because of their personal background and expertise, not as representatives of their organizations.
2 About dogs…

Early domestication is thought to have occurred when humans
captured young wolves and selectively bred those that were tame

*a report of t4 – the transatlantic think tank for toxicology, a collaboration of the toxicolgically oriented chairs in Baltimore, Konstanz and Utrecht
sponsored by the Doerenkamp-Zbinden Foundation
† This workshop was held in memory of Hildegard Doerenkamp (1920 – 2011), the philanthropic cofounder of the Doerenkamp-Zbinden Foundation.
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and sociable, so that human interaction played a significant role
in shaping the subspecies (Miklosi, 2007). Domestic dogs have
been selectively bred for various behaviors, capabilities, and
physical attributes (Dewey and Bhagat, 2002). In the past the
relationship between humans and dogs was often more practical
and so humans provided food, shelter and social contacts, while
the dog contributed by herding, protection and hunting. Pet dog
populations grew significantly after World War II as urbanization increased (Derr, 2004) and in the 1950s and 1960s, dogs
were still kept outside more often than today (Franklin, 2006).
In many Western countries and Japan dogs are now included in
families and homes (Power, 2008).
In Europe approximately 62 million households own at least
one pet, and it is estimated that these include 60 million cats and
56 million dogs1. It is well established that the companionship
of a pet can enhance human physical health and psychological
well-being by reducing stress and blood pressure (Podberscek,
2006). Pet owners have been shown to have better mental and
physical health, making fewer visits to the doctor and being less
likely to be on medication than non-owners (Headey, 1999).
Dogs are also used to help disabled people: in Europe some
13,000 guide dogs assist the blind, the deaf and people with
physical disabilities. They are also trained as disaster dogs to
help after earthquakes or avalanches, as police dogs, searching
for missing people or for security tasks such as finding explosives and drugs2.
Pets even create their own market for food and care accessories. According to a FEDIAF (European Pet Food Industry)
“Facts & Figures” document3 the sales of pet food and other
related products and services has a turnover of € 24 billion with
a growth rate of 2% annually.
When describing the dog’s role in society it should be mentioned that there are cultural differences. For example, in some
East Asian countries, including Korea, China, and Vietnam, dog
meat is eaten by humans and it is estimated that 13-16 million
dogs are consumed in Asia every year4 – a practice that dates
back to antiquity.
3 The animal welfare perspective

The Sixth Report5 from the European Commission on the number
of animals used for experimental and other scientific purposes in
the Member States of the European Union in 2008 states that 12.2
million vertebrates were used including 21,315 dogs.
The protection of animals, as anchored in the EU Treaty of
Amsterdam of 1999, and amended by the Treaty of Lisbon in
2009, is a major goal that the Union should respect: “In formulating and implementing the Union’s agriculture, fisheries, transport, internal market, research and technological development
and space policies, the Union and the Member States shall, since

animals are sentient beings, pay full regard to the welfare requirements of animals, while respecting the legislative or administrative provisions and customs of the Member States relating
in particular to religious rites, cultural traditions and regional
heritage.” This is also the major goal of the Directives 86/609/
EEC and 2010/63/EU (Hartung et al., 2010a) on the protection
of animals used for scientific purposes, the European Convention ETS 123 and the individual Animal Welfare Acts of the EU
Member States. The Community Action Plan 2006-2010 and the
EU Strategy for Protection and Welfare of animals 2011-2015 to
be adopted in December 2011 will further this goal6.
From an animal welfare perspective, concerns arise from
the fact that animal experiments cause pain, distress and harm.
Housing may restrict “natural” behavior and some animals may
develop dysfunctional behaviors. Stressors can also include other issues, such as transport. Moral concerns as well are raised
by the fact that in most cases the animal is euthanized at the end
of a procedure, although in some cases dogs may be retired and
re-homed.
Further, the discussion regarding the benefits of animal research for humans (Hartung, 2008a) still is controversial. A final
goal of 3Rs developments should be to replace all animal experiments by scientifically valid human cell or other models, but
where this is not possible the other principles of “Reduction”
and “Refinement” should be applied. The public is particularly
concerned about the use of distinct animal species, such as dogs
and monkeys, and some argue that these species should be given
special protection. Although some legislation, such as the UK
Animals (Scientific Procedures) Act from 1986 does make such
special provisions for dogs, others do not.
There is little public information available about the use of
dogs; therefore, a survey was carried out by the DoerenkampZbinden foundation in six randomly chosen European countries
over the period from 2004-2006 on publicly available information, taking into account the EC Report as well as online search
tools like PubMed and Google Scholar. Very limited information could be retrieved, for example on the detail of experimental procedures, making it impossible for the public to assess the
severity of experiments, numbers of animals used in any particular experiment and the level of pain and distress inflicted.
The number of animals used is known from public statistics,
but the procedures used on the animals cannot be found in the
scientific literature. Publications from the six surveyed countries, which represented roughly half of the EU animal use in research, accounted for only 800 of the approximately 20,000 dogs
used in Europe, most probably due to the following points:
– Not all papers are published in English.
–	Experiments are often not published when they have not produced positive results or were aborted.
–	Experiments that are performed in private laboratory facilities and/or companies, where the results are used to fulfill le-

1 http://www.ifaheurope.org/CommonTP.aspx?SubMenuId=58&MenuId=17
2 http://www.ifaheurope.org/html/document.aspx?id=43&hash=ba7621fbb5e28c3efe215a2270c08ca6
3 http://www.fediaf.org/facts-figures/
4 http://www.animalpeoplenews.org/03/9/dogs.catseatenAsia903.html
5 http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2010:0511:REV1:EN:PDF
6 http://ec.europa.eu/food/animal/welfare/actionplan/actionplan_en.htm
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gal requirements, are submitted to the respective authorities
rather than being published in the peer-reviewed literature.
–	Experiments published in the cited year might have been carried out long before the year of publication.
To support ethical committees and prevent duplication of procedures an easily accessible online database might be useful,
where research facilities can share their data. This was considered an attractive idea by most of the workshop participants, but
the practical difficulties might be huge. Most of the pharmaceutical testing is done on new compounds, so the comparison of
data might be difficult. A certain degree of privacy protection
might help to overcome most of the other concerns.
4 Moral dilemma

The current relevance of animal welfare issues is strongly
based on societal concerns about how animals are treated. In

order to deliver solutions to perceived welfare issues, animal
welfare scientists must take both the societal perception and scientifically based considerations into account: The recommendations they make regarding animal welfare issues must comply
with the moral values of society in order to generate sustainable
approaches. For doing so, a systematic approach is needed to
identify potential moral dilemmas in animal welfare and factors
that might influence these dilemmas. The Dutch Animal Welfare Council recently developed such an approach, the so-called
ethical framework7, demonstrated in Figure 1, to structure discussions about the ethical dimension of current and potential
future animal welfare issues. Such a discussion should cover
what needs to be done from a moral perspective in any given
situation, identify relevant ethical issues (specifically in relation
to animal welfare), and outline the steps that need to be taken to
resolve these issues. It should be clear that such a framework is
intended to identify relevant ethical issues and potential moral
dilemmas rather than to yield straightforward solutions. FurFig. 1: Framework
to structure
discussions about
ethics
The aim of this
framework (adopted
from RDA, 2010) is to
structure discussions
about the ethics of
the use of dogs as
experimental animals.
Such discussions
should cover what
we should do from
a moral perspective
in a given situation,
identify relevant
ethical issues, and
outline the steps that
need to be taken to
resolve this issue
(kindly provided
by Frauke Ohl,
University of Utrecht,
The Netherlands).

7 http://www.rda.nl/pages/adviezen.aspx
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thermore, the results of these considerations will not be universally valid but will differ significantly between societies. The
importance of such a framework is that it provides a basis for
discussion of animal welfare within a given society.
From the scientific point of view some people may conclude,
that the dog represents an animal model of better validity for
distinct research questions than other animal models, while
other scientists strictly disagree. Given the presupposition that
all animals have an intrinsic value, one must conclude that the
choice of animal species for experimental purposes needs to be
based on objective criteria such as model validity. On the other
hand, an ethical justification for replacing dogs with another
species may be difficult to find. However, it has to be acknowledged that the emotional value of dogs for humans does result in
a moral dilemma, not only within the broader society, but often
as well for humans conducting experiments.
While we therefore do not oppose the societal wish to direct
special attention to the application of the 3Rs to the use of dogs
in experimental research, we wish to emphasize that this approach may result in the use of less valid models or may require
a higher number of animals to obtain reliable results.

of products and devices for human medicine and dentistry and
for veterinary medicine”. This is in contrast to overall experimental animal use, where toxicology and other safety evaluations count for 8.7% of all animals used. Nearly a quarter of all
dogs are used in “Research and development of products and
devices for human medicine and dentistry and for veterinary
medicine”, whereas “Production and quality control of products
and devices for veterinary medicine”, “Biological studies of a
fundamental nature” and “Diagnosis of disease” comprise the
last quarter of total dog use.
Our report will focus mainly on toxicological and other safety
evaluations, biomedical research, and the development of products, but will mention also some examples of dog use which
might not be that prominent, e.g., the dog as a genetic model.
While most genetic work is carried out in mice, there are 220
homologous hereditary diseases with uniform genetic mutations shared by dogs and humans, where research on dogs is
thought by some scientists to give deep insight, knowledge, and
understanding of disease mechanisms and possible cures, e.g.,
bleeding disorders (haemophilia A and B), leukocyte adhesion
deficiency, retinal degeneration (retinitis pigmentosum) and
narcolepsy, while other scientists disagree.

5 Main areas of dog use

5.2 The two-species paradigm

5.1 In general

Historically, the use of dogs as animal models for research and
testing evolved because of their availability, size, and the ease
of use. Their anatomy and physiology are similar in many aspects to those of humans. As adapted from the European Commission Staff Working Document8, which accompanied the Report on the number of animals used for experimental and other
scientific purposes, and shown in Table 1, more than 50% of
all dogs are used in “Toxicological and other safety evaluations

In 1965 the US FDA (Food and Drug Administration) introduced the two-species paradigm, by which non-rodent species
are required to provide sufficient data to pick up drug effects not
observed in the rodent species. The second-species paradigm is
still applied today, is mandatory in many cases, such as in the
guidance of FDA, CHMP (Committee for Medicinal Products
for Human Use), ICH (International Conference on Harmonization), and the OECD (Organization for Economic Co-operation
and Development). Pharmaceutical and agrochemical companies are presented with limited alternatives and commonly the

Tab. 1: Areas of dog use
Adapted from the Table “Number of animals used in experiments for selected purposes data of 2008 in Europe 27*”
from the European Commission Staff Working Paper – Accompanying document to the Report from the Commission to
the Council and the European Parliament on animal numbers used for scientific purposes
Biological studies of a fundamental nature

1841

Research and development of products and devices for human medicine and dentistry and for veterinary medicine
(excluding toxicological and other safety evaluations)

4405

Production and quality control of products and devices for human medicine and dentistry
Production and quality control of products and devices for veterinary medicine
Toxicological and other safety evaluations (including safety evaluation of products and devices for human medicine
and dentistry and for veterinary medicine)
Diagnosis of disease
Education and training
Other
All dogs used in 2008

157

2070
11077

1111

362

316

21312

*(France reporting for 2007)
As stated in the Commission staff working paper: “Other” covers a wide range of experiments such as virology, immunology for
production of monoclonal and polyclonal antibodies, physiology of fetal-maternal interaction in mouse gene transgenesis, oncological
treatment, pharmaceutical research and development, combined drug testing and genetics.
8 http://ec.europa.eu/environment/chemicals/lab_animals/pdf/sec_2010_1107.pdf
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Tab. 2: The dog as 2nd species in EU legislation on chemicals, biocidal and plant protection products
(Kindly provided by Kristina Wagner, German Animal Welfare Federation); emphasis added.
Explicit
requirement of
use of dogs

EU legislation

Endpoint

Test method / Study

REGULATION (EC)
No 1907/2006 (REACH):
Annex 9,
information requirements
for substance quantities of
100 tonnes and more

8.7. Reproductive
Toxicity

NO

REGULATION (EC)
No 1907/2006 (REACH):
Annex 9,
information requirements
for substance quantities of
100 tonnes and more

8.7. Reproductive
Toxicity

8.7.2. Pre-natal developmental toxicity study, one
species, […] (B.31 of the Commission Regulation on test
methods as specified in Article 13(3) or OECD 414).
Specific rules for adaption from standard information required
[…] A decision on the need to perform a study at this tonnage
level or the next on a second species should
be based on the outcome of the first test and all other relevant
available data.

8.9.4. Further repeat dose studies
ADS [ADS=additional data set]
“Further repeat dose studies including testing on
a second species (non-rodent), […]

NO

Regulation EC 440/2008
(Commission Regulation on
test methods),
Annex B.

B.27. Sub-chronic
oral toxicity
repeated dose in
non-rodents (90 d)

“The commonly used non-rodent species is the dog, […]” YES
(This sub-chronic oral toxicity test method is a replicate of
OECD TG 409)

B.30. Chronic
toxicity test

[…] The preferred species is the rat.
Based upon the results of previously conducted studies
other species (rodent or non-rodent) may be used. […]
[…] For non-rodents a smaller number of animals, but at
least four per sex per group, is acceptable. […]

NO

5.3.2. Oral 90-day study
[…] The short-term oral toxicity of the active substance to
rodents (90-day), usually the rat, a different rodent species
shall be justified, and non rodents (90-day toxicity study
in dogs), shall always be reported. […]

YES

5.8.2. Supplementary studies on the active substance
[…] a) studies on absorption, distribution, excretion and
metabolism, in a second species, […]

NO

8.9. Repeated
Proposal for a REGULATION
dose toxicity
OF THE EUROPEAN
PARLIAMENT AND OF THE
COUNCIL concerning the
placing on the market and use
of biocidal products, (Political
agreement reached in Council;
2009/0076 (COD))
Annex II, Active Substances,
Title 1, Chemicals

OECD Test Guidelines for the
testing on chemicals

Draft Regulation laying
down test methods / Data
requirements for Active
Substances in Plant
Protection Products (SANCO
11802/2010),
ANNEX II,
Part A,
Chemical active substances

330
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B.3. Acute toxicity
(dermal)

TG 409
Repeated Dose
90-Day Oral
Toxicity Study in
Non-Rodents
5.3. Short-term
toxicity

8.7.3. Two-generation reproductive toxicity, one species, male
and female, […]
Specific rules for adaption from standard information required
[…] A decision on the need to perform a study at this tonnage
level or the next on a second species should be based on the
outcome of the first test and all other relevant available date.

[…] The adult rat or rabbit may be used. […]
Other species may be used but their use would require
justification.
[…] Note: in acute toxicity tests with animals of a higher
order than rodents, the use of smaller numbers should
be considered. […]

NO

NO

“The commonly used non-rodent species is the dog, […]” YES

5.5. Long term toxicity and carcinogenicity
[…] If comparative metabolism data indicate that either rat
or mouse is an inappropriate model for human cancer risk
assessment, an alternative species could be considered if
justified.

NO
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dog is used as the second non-rodent species. In Table 2 the
“German Animal Welfare Federation” summarized EU legislation on chemicals, biocidal products and plant protection products that requires a second species, with special emphasis on the
requirement of the dog.
5.3 Regulatory toxicology

Pharmaceuticals
An Industry/Welfare Steering Group (Smith et al., 2002) reviewed the areas where dogs are used. Safety pharmacology
includes studies performed during the early development of a
drug, before a first clinical trial. These studies may use dog tissue
and organs for in vitro cardiovascular assessment. Non-recovery
studies involving anesthetized dogs may be performed to assess
hemodynamics, cardiovascular parameters, respiratory and renal
functions. The less invasive model uses telemetered, conscious
dogs to assess the cardiovascular system, thereby satisfying the
regulatory demand of the safety pharmacology core battery.
Cardiovascular side effects have been among the most frequent causes for drug withdrawals, which eventually led to the
first international regulatory guideline on safety pharmacology
(ICH S7A)9 in 2000 to ensure the safety of human volunteers and
patients participating in an early phase of clinical trials. Though
safety pharmacology testing was done before the guideline, a
global harmonization component was added by its implementation. The “Safety Pharmacology Core Battery” was developed
to assess drug effects on the functions of critical organ systems,
e.g., cardiovascular, central nervous and respiratory function. In
2005 “The Nonclinical Evaluation of the Potential for Delayed
Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals” (ICH S7B) was introduced. Both guidance documents anticipated dog use with different emphasis of
the role of in vitro and in vivo studies.
Dog studies are performed with single or multiple doses (fixed
or ascending) to determine dose selection and to assess target
organ toxicity, Maximum Tolerated Dose and Dose Range Finding (MTD/DRF). Often the study starts with an ascending dose
in few animals until first signs of toxicity occur, is continued
with a EIH (Enter Into Humans) GLP (Good Laboratory Practice) study requiring a sufficient number of animals to assess
target organ toxicity and reversibility, determine the safe starting dose, derive safety margins and set the ceiling exposure to
support clinical planning, and ends with a long-term GLP study
with a statistically valid number of animals to support long-term
clinical studies and marketing. Repeat Dose is the pivotal study
in a regulatory package in pharmaceutical development and durations of 14 days to 1 month, 3 months, and 9 to 12 months
are generally used. In some cases, some of these studies may
be omitted depending on the clinical program (duration of human studies) or the therapeutic indication (6 months studies are
sufficient for some countries or indications). Study designs are
generally well defined and include extensive in-life monitoring,
e.g., ECG (electrocardiography), hematology, clinical chemistry, ophthalmology and detailed histopathology.

Changes in regulatory toxicology testing were often driven
by tragedies (e.g., thalidomide; Kim and Scialli, 2011), and the
liability of producers for their product, and the safety of volunteers and patients for the drug under investigation created the
need for testing. Every new incidence has added another patch
of safety measures and guidelines, some of them dating back
to the 1960s and earlier, based on the belief that more in vivo
testing would solve the problem, but often largely unmodified
with difficulties to adapt to new scientific advances (Hartung,
2009a, 2011). Testing should take place not as a default but on
a need-to-know basis and there are cases where this paradigm is
applied. An example is the guideline ICH S9, which regulates
anti-cancer drugs for patients at the terminal stage, and neither
long-term toxicity studies, nor fertility or pre- and post-natal
studies are generally required. Therefore, the need to perform
studies on non-rodent species is limited here, and they are basically used for short-term studies and embryo-fetal development,
mainly carried out in rabbit or monkey.
Chemicals
In chemical development, studies with repeated dosing up to
13 weeks are usually sufficient for filing. In some territories, e.g.,
Japan and Brazil, regulatory authorities still expect data covering
6 months, which means that these studies are still conducted,
even though they are considered unnecessary by the US and EU.
Juvenile studies
Toxicity studies for drugs intended for use in children and adolescents represent another potential requirement of regulators
to allow clinical pediatric drug development. The safety and
efficacy for children and adolescents has not been studied in
animals systematically until recently and the default conclusion
was that a new drug is not recommended for use in children
and adolescents due to lack of data. The design of these studies
is often similar to those of repeat dose studies but using very
young animals. The species is not explicitly prescribed, but the
choice should be appropriate for evaluating toxicity endpoints
relevant to the intended pediatric population and both sexes are
obligatory. Standard non-clinical studies using adult animals, or
safety information from adult humans, cannot always adequately predict these differences in safety profiles for all pediatric
age groups, especially effects on immature systems that undergo postnatal development, such as the brain, the pulmonary
system, the kidneys, the reproductive system, the immune system, the skeletal system and even other organs or tissues which
may play a critical role in the pharmacokinetics of a medicinal
product10. This point has to be taken into special consideration,
because it might lead to new testing requirements for other distinct populations in addition to juveniles, e.g., the elderly, and
diabetic or immune-compromised patients.
Pesticides
For pesticide testing, one rodent and one non-rodent species are
required. Dogs are used as non-rodent species for oral subchron-

9 http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf
10 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003305.pdf
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ic and chronic toxicology studies. In many cases, the dog appears to be more sensitive than the rat, i.e., they show effects
at lower doses. Notably, new regulations have been adopted in
the US that eliminate the one-year chronic toxicity study in the
non-rodent; the subchronic 90 day study is considered sufficient
because meta-analysis showed that there is no significant additional information obtained from a longer study (Kobel et al.,
2010). EU regulations are also changing to allow a 90 day study
without the need for a one year study, but unfortunately Japan
and Brazil still require the one year test. Thus, a European or US
company intending to sell to the Japanese or Brazilian market
must still perform a one-year study in the non-rodent, i.e., dog.
Non-pharmaceuticals
For some non-pharmaceutical products, e.g., agrochemicals and
biocides, it is explicitly indicated that the dog is the first choice
as a non-rodent species for toxicity testing. This approach appears to be based on historical experience and tradition rather
than scientific rationale, but is strongly supported by Guidelines.
OECD 409 demands: “The commonly used non-rodent species
is the dog, which should be of a defined breed” and OPPTS
870-3150 states specifically: “The commonly used non-rodent
species is the dog, preferably of a defined breed; the beagle is
frequently used. If other mammalian species are used, the tester
should provide justification/reasoning for his or her selection.”
5.4 Other areas

Non-clinical tests on dogs are also conducted for certain alimentary products and veterinary medicines. Dog research is also
done on diseases and conditions particular to dogs, including
chronic pain, hip dysplasia and behavioral diseases. Conditions
in specific breeds like mast cell tumors in Labrador Retrievers,
rage syndrome in English Springer Spaniels or inflammatory
bowel disease in Boxers are among the numerous examples that
have prompted specific studies.
6 The selection of the second species

Directive 2010/63/EC, Recital 13 states that “The choice of
methods and the species to be used have a direct impact on both
the numbers of animals used and their welfare. The methods
selected should use the minimum number of animals that would
provide reliable results and require the use of species with the
lowest capacity to experience pain, suffering, distress or lasting
harm that are optimal for extrapolation into target species.”
Traditionally, the dog is considered the non-rodent species of
first choice, due to the fact that Beagles are purpose-bred and
easily available and knowledge on their physiology is extensive.
The choice of non-rodent species in toxicological programs has
to be specifically justified based on scientific evidence relating to
the predictability of the animal model for the specific function.
All available information, like in vitro data and state-of-the-art
literature, must be taken into account to ensure the choice of the
best model. Species selection must be made on a case-by-case
basis, indicating scientific justification, ethical perspectives,
technical considerations, and regulatory acceptability, weigh332
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ing the pharmacological activity of the drug, the pharmacokinetic profile allowing sufficient exposure, and analysis of the
metabolism and its similarity to humans. Best scientific practice
and therefore enhanced consumer safety requires using the best
model, not the one that is most easily available. It always should
be kept in mind that species choice needs to be specific to the
compounds under investigation. That would also suggest that
academia and industry should publish their findings to avoid
unnecessary duplicative testing. Some examples of limitations
in the use of dogs are given in Table 3.
The use of dogs as a second species in safety evaluations is
closely linked to a long-lasting discussion on multiple species
toxicity testing in general. Retrospective analyses of the additional value of dog studies over rodent studies have been published
in the area of pesticide testing, where extensive information is
available in several national registers (Gerbracht and Spielmann,
1998; 2001; Box and Spielmann, 2005; Kobel et al., 2010). Such
studies indicated early on, that for instance mouse data provide
no gain of knowledge, when rat and dog data are available. However, detailed analysis of chronic and subchronic toxicity studies
also indicated that the dog is the more sensitive species (when
compared to rats) in about 15% of all cases. Thus, the dog studies
contributed clearly to the definition of the NOEL (no observed
effects level). Since the NOEL is used as point of departure for
safety regulations, dogs were required in the field of pesticides
according to these retrospective surveys of several hundred compounds (Box and Spielmann, 2005; Kobel et al., 2010). However,
more detailed analysis also examined the need for long-term (12
month) dog studies, in addition to shorter studies (90 days), and
the conclusion of international regulatory experts was that dogs
as second species for long term studies beyond 13 weeks are dispensable (Kobel et al., 2010; Dellarco, 2010).
Some retrospective data are also available from the field of
pharmaceuticals. A study by Olson (Olson et al. 2000) compared human toxicities of about 150 drugs with the respective
preclinical toxicity data obtained in rodent and non-rodent species. They used this data base to investigate the predictive value
of the two-species approach. They found that a better test sensitivity was obtained when data from two species (e.g. dog and
rat) were combined. Non-rodent data from either non-human
primates or dogs taken together with rodent data predicted human toxicity in 71% of all cases, while rodent data only predicted 43% of human toxicities.
This study is often taken as evidence that the non-rodent species is indispensable for human safety assessment, and that inclusion of several species increases test sensitivity. However, it
is also well-known that this approach invariably decreases test
specificity and leads to a large number of false positive results
(Hartung, 2009a). As the authors of the Olson report themselves
admitted, “A more complete evaluation of the predictability aspect will be an important part of a future prospective survey.”
A statistician elaborated on this in 2008 (Matthews, 2008), and
concluded: when the correct definitions of sensitivity, specificity and likelihood ratio are used, “the data provide no statistically
credible evidence that these animal models [dogs and monkeys]
contribute any predictive value, either separately or in combination.” Therefore, some scientists conclude that published data
Altex 28, 4/11
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Tab. 3: Limitations for the use of dogs with examples of oversensitivity
Limitations for the use of dogs

Examples of oversensitivity

Convulsions

dose-limiting

Emesis*

insufficient exposure or erratic dosing

Non-steroidal anti-inflammatory drugs

GIT lesions

Vasodilators & anti-hypertensives

arteriopathy & cardiotoxicity

Hormones

females may be very sensitive to estrogens and anti-estrogens

Drugs causing histamine release

dose-limiting due to pseudo-allergy

*Emesis is controversially discussed (du Sert et al., 2011).

to demonstrate the need for dogs in drug safety testing is lacking, and that it is possible to achieve a reduction and refinement
in dog use without compromising human safety (Broadhead et
al., 2000). Since both drug testing and also general biological
knowledge have changed considerably during the last 10 years,
new comprehensive retrospective evaluations would shed more
light on the predictivity, sensitivity and specificity aspects of
using dogs in safety evaluations. We suggest such studies, applying the principles of evidence-based toxicology (Hofmann
and Hartung 2006; Hartung, 2009b), to provide a more solid
scientific basis for future discussions on this topic.
In order to respond to public concerns toward laboratory dogs
an EU FP6 Specific Support Action (SSA) project called “RETHINK” was initiated to investigate the feasibility of the minipig as an alternative model for regulatory toxicity testing. RETHINK was a multinational project, co-funded by the European
Commission, consisting of 5 Working Groups, where several
invited experts from the European Union reviewed the impact of
toxicity testing in mini-pigs over the period 2006-2008 including
an evaluation of the potential 3Rs contribution. The results were
published in 2010 in a special issue of the Journal of Pharmacological and Toxicological Methods (Forster et al., 2010).
Over the last ten years there has been a reduction of the use of
dogs and a concurrent increased interest and acceptance of minipigs as an alternative non-rodent species in accordance with the
RETHINK conclusions. They recognized areas where a case-bycase analysis will favor the use of the mini-pigs over the dog in toxicology and drug development. The workshop participants agreed
that replacing one sentient being by another equally sentient one
cannot be called a 3Rs initiative, and should not be the final goal.
An EFPIA document of species selection is currently in preparation and builds on the “Points to Consider” document published jointly in 2002 in the UK by the ABPI (Association of
British Pharmaceutical Industry) and the Home Office11.
7 The dog as a new “natural model”
for human behavior

As already mentioned, humans and dogs have coexisted in
close proximity for a long time, sharing the same nutrition, life

style and living environment. Certainly dogs have influenced
humans but humans have influenced dogs much more by selective breeding, therefore enhancing certain phenotypes. Studies
are ongoing in canine science, cognitive ethology, dog-human
communication as well as the dog-wolf comparison (Gácsi et
al., 2005) exploring the dog as a natural model for human behavior (Miklósi, 2007). Dogs may help to trace human behavioral evolution by evaluating human species-specific behavioral traits that possibly evolved after the “pan” and “homo” split
(approx. 6 million years ago) with those of the dogs having
evolved around 15-25,000 BC. This convergence in dog social
behavior led to a nearly symbiotic relationship between these
two species. The natural environment for a dog is the one offered by a human being.
This idea led to studies in which an association of a polymorphism in the dopamine D4 receptor gene and the (hyper-)
activity of dogs was discovered (Hejjas et al., 2007), which
in turn led to observations regarding human ADHD (attention
deficit hyperactivity disorder). Furthermore, a potential cure
may have been identified, as indicated by the discovery that
dietary supplementation with medium-chain triglycerides resulted in long-lasting cognition-enhancing effects in aged dogs
(Pan et al., 2010).
For some scientists dogs may provide a good “natural model”
for studying behavior, while others disagree. Nevertheless, if
these studies are conducted, emphasis has to be put on the methods used to measure the behavioral phenotype. These methods
should lead to the development of ecologically and socially
valid tests, and the introduction of non-invasive testing methods
that are the basis for a sound analysis. These kinds of studies
may be helpful to develop tools to determine and measure animal welfare, which would be a prerequisite to further improvement in the area of refinement.
8 Canine models of human inherited disorders

Dogs are being used in attempts to further understand and elucidate human diseases and contributions of about € 12 million are
given by the EU for canine disease genetics12, acknowledging
the potential value for human health. Some people may assume
that dogs are clinically and physiologically closer to humans

11 http://www.abpi.org.uk/our-work/library/guidelines/Pages/non-rodent.aspx
12 http://www.eurolupa.org/
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than tiny rodents and that human and canine diseases progress
more similarly, others may disagree.
The various dog breeds carry unique breed-specific variations
in morphological and behavioral traits and more than 600 genetic disorders are described with around 70% of the diseases having corresponding human conditions. Dogs have the advantages
of a large pedigree and a unique population history of around
9000 generations with a unique breed structure of more than
400 genetic isolates (Karlsson and Lindblad-Toh, 2008).
These characteristics may lead, for some scientists, to the
conclusion that the dog might be a natural model for human disorders like epilepsy, separation anxiety, obsessive-compulsive
behavior, and aggression. A large dog DNA bank has already
been established where several new loci and genes have been
identified for different diseases, most of them as new candidates
for corresponding human disorders. The process is non-invasive
and requires only the dog owner’s consent, a blood sample and a
phenotype characterization by completion of a questionnaire.
This knowledge opens a new area of discussion on the use
of dogs. One option might be to simply exclude animals with
genetic defects from breeding, but this may raise new ethical
issues, because pharmaceutical companies and biomedical research scientists might consider using these animals under purpose-bred conditions to find and develop new drugs.
9 Replacement

Replacement, as introduced by Russell and Burch as a part of
the 3Rs principle for humane experimental technique in 1959
(Russell and Burch, 1959), refers to methods that avoid or replace the use of animals, where they would otherwise have been
used. Replacement methods can be absolute replacements –
techniques that do not involve live animals at any point, such
as computer modeling, cell culture and tissue engineering or
other in vitro methodologies – or relative replacements, which
replace the use of (higher) animals by non-sentient species13.
In Recital 10, European Directive 2010/63/EU clearly identifies
full Replacement procedures on live animals for scientific and
educational purposes as the final goal, “as soon as it is scientifically possible to do so.” Furthermore, the Directive states in its
Article 4, Part 1: “Member States shall ensure that, wherever
possible, a scientifically satisfactory method or testing strategy,
not entailing the use of live animals, shall be used instead of a
procedure.”
Unfortunately, there are no methods or strategies available at
the moment to ensure a full Replacement of experiments on dogs,
so the main research effort and funding should be directed towards the development of such methods. Scientific and technical
progress are moving fast and new and promising methods are
being developed constantly, so it will be a question of identifying
or promoting those that are suitable to address scientific questions and satisfy the needs for more humane and evidence-based
safety testing. These methods and techniques also will need to be
internationally accepted and to be integrated in testing strategies.

Tox-21c (NRC, 2007; Krewski et al., 2010), i.e., the vision put
forward by the 2007 publication of the US National Research
Council “Toxicity Testing in the 21st Century: A Vision and a
Strategy”, offers a completely new way of approaching toxicology by identifying pathways of toxicity (Hartung and McBride,
2011, Andersen et al., 2011), looking at modes of action, and developing in vitro tests which are directly guided to the mechanism of toxicity instead of the “black box approach” the animal
provides. Though this vision has no aspect specific to dog use,
it has created a spirit of optimism that the replacement of currently conducted animal testing by mechanistically based higher
throughput tests can be possible (Hartung, 2008a; 2010b; Hartung and Koëter, 2008; Hartung and Leist, 2008), using human
cells (Leist et al., 2008; Kuegler et al., 2010), response pathways
(Alon, 2007), and evidence-based procedures (Hoffmann and
Hartung, 2006; Hartung, 2009b) to develop scientifically sound
“Integrated Testing Strategies” (Jaworska and Hoffmann, 2010).
There are ongoing efforts in which experts from animal welfare organizations work together with regulators to produce new
drug development guidelines for the use of alternative methods
to replace animal use.
10 Reduction

The approach to the reduction of dog use was addressed by a
UK “Industry/Animal Welfare Initiative to minimize dog use
in preclinical toxicology” following a workshop on “The dog
in regulatory toxicology” (Smith et al., 2002). A Consortium
of European pharmaceutical companies, including the Fund for
the Replacement of Animals in Medical Experiments (FRAME)
and the Royal Society for the Prevention of Cruelty to Animals
(RSCPA), was formed, supported by the European Federation
of Pharmaceutical Industries (EFPIA) and the Association of
the British Pharmaceutical Industry (ABPI).
The project was divided into three phases covering (1) Best
practice in study design (Refinement/Reduction/Replacement),
(2) Industrial co-operation and data sharing (Reduction), and (3)
Assessing the need for particular studies (Replacement).
In phase 1 (Best practice in study design) different approaches were investigated:
– Design of preliminary studies
– Group sizes for repeat-dose studies
– Use of single sex studies
–	The need for recovery groups
–	The use of control animals
– Overall program design
Preliminary studies are usually conducted outside of the regulatory framework because they are used to collect information for
future studies, particularly dose range finding and the maximum
tolerated dose. Through analysis of an industry questionnaire
the group found that there was no consensus on design or power
of the studies conducted. Furthermore, in 12 responding companies, 15 different study designs were used with variations in
many design aspects and in numbers of dogs. The results opened

13 http://www.nc3rs.org.uk/page.asp?id=7
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the opportunity to develop a harmonized design by reviewing
the intended purpose of the study with regard to numbers of
animals and outcome of the 14- or 28-day study. The primary
purpose is dose selection (high dose) for the pivotal repeat dose
study and the secondary purpose is the detection of serious toxicity. In this way candidate drug selection can be confirmed and
an estimation of compound requirements and toxicokinetic data
can be obtained. Thus, a preliminary prediction of dose levels
for 14- or 28-day studies can be made based on a low number of
animals used (9-12 animals showed best results). After a thorough review, harmonization of the principal study design was
proposed, which led to a reduction in dog use by applying the
optimized design and endpoints (Smith et al., 2005)
Phase 2 consisted of a data-sharing initiative to avoid unnecessary duplication of studies within pesticide, chemical and
pharmaceutical sectors. The authors also supported the development of a central database of animal experiments, including
a vehicle database containing in vivo toxicological information
on non-active formulation ingredients (vehicles, solvents, excipients, preservatives, etc.) and selected chemicals, in terms of
its potential to share qualitative and quantitative data between
interested parties. The database is hosted by Lhasa Ltd. It offers free access for collaborating companies and operates with a
search fee for outsiders.
In phase 3, the assessment of the need for particular studies
took place and suggestions were to eliminate the terminal 3 or 6
month study by maximizing data from safety pharmacology in
1 month studies, using interim readout from the 9 or 12 month
study combined with non-destructive sampling. Unfortunately,
it is necessary to wait for the outcome of biomarker/-omics
projects before proceeding with this part of the project.
The impact of these best practices in MTD/DRF study design
initiative was estimated to account for a reduction by 40-120
dogs/company/year, the elimination of acute toxicity testing
(for Japan) saves 8-16 dogs/company/year and standardization
of group sizes for repeat dose studies resulted in small gains. A
2006 survey in the UK showed that the removal of control recovery groups might be able to save 120 dogs per year, but some
companies are still concerned about the scientific and regulatory
repercussions of that question (Smith et al., 2007).
11 Refinement

There are a number of resources already available to assist with
refinement of dog care and use (Wells, 2004; Hubrecht and Kirkwood, 2010). They provide an extensive collection of recommendations on housing, physical environment, food and feeding, environmental enrichment, exercise, health and hygiene,
breeding, balancing supply and demand, grouping, transport,
handling and restraint, procedures, long-term use, re-homing,
staff training and areas for future research to refine further dog
husbandry and care (BVAAWF/FRAME/RSPCA/UFAW Joint
Working Group on Refinement, 2004).
The main breed used in laboratories is the Beagle and, in
Europe, animals used in experiments must be purpose-bred.
To minimize the creation of surplus animals all possible measAltex 28, 4/11
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ures should be taken to ensure the supply of animals does not
exceed demand. Dog housing should aim to meet the physical,
physiological, behavioral and social needs and as a guiding
principle, housing and husbandry should be managed in order
to allow animals to perform a wide range of species-specific
behaviors.
The dog is a social, macro-osmatic, neophyllic (inquisitive)
omnivore that, when feral, can range over large areas (28.5 km2).
Research on carnivores shows that those with large ranges tend to
fare worse in captivity (Clubb and Mason, 2003; Hubrecht et al.,
1992). Minimum space allowances set down in codes of practice
or legislation tend to be relatively small (Tab. 4), therefore, it may
be difficult to provide kenneling in a research environment that
meets the dog’s needs in total.
Even in the largest of these (4.5 m2) some dogs develop behavioral abnormalities. What is put into the space in terms of
enrichment, etc., may well be more important than a few square
centimeters of space; however smaller spaces provide fewer opportunities to provide enrichment, complexity and control for
the dog.
Outdoor runs may be beneficial in providing greater complexity and interest (Hubrecht, 1993; Spangenberg et al., 2006).
Dogs should be housed in socially harmonious pairs or groups
and additional human socialization should be provided as it has
been shown that petting lowers blood cortisol (Hennessy et al.,
1998; Tuber et al., 1996). Social isolation should be avoided.
Environmental enrichment is crucial (Hubrecht, 1995) and enrichment items should be provided and presented in a way as to
maintain interest and activity to avoid frustration and boredom
(Pullen et al., 2010). The effects of enrichment should be closely
monitored. Chewing is an important behavior and items should
be provided to meet this need. Social enrichment (both dog-dog
and dog-human) and adequate physical and mental stimulation
are also crucial, therefore exercise periods should be provided
ideally on a daily basis. Noise levels can be a problem, but can
be reduced by facilities that meet the animal’s needs and by suitable building design. Dogs should never be debarked.
Stereotypies are an indicator that there is a welfare issue
(Clubb and Mason, 2003) and the aim should be to avoid their
occurrence rather than dealing with them once they have appeared. Behavior of dogs should be monitored in order to detect
behavioral abnormalities and other signs of poor welfare. Indicators of acute and chronic stress are summarized in Table 5 as
published in Beerda et al. (1997, 1998, 1999a,b).
If dogs do develop behavioral abnormalities, housing and
husbandry practices should be examined and changed so that
such behaviors are eliminated.
To improve the welfare of dogs used in biomedical research
and testing, more research is needed. Observational studies to
understand responses to changes in husbandry via preference
and choice tests plus motivational demand studies to understand
the cognitive state may be useful. The dog’s olfactory sense is
103-108 times more sensitive than ours, but there have been
relatively few studies on olfactory enrichment (Graham et al.,
2005) or on auditory enrichment (Wells et al., 2002).
Dogs’ vision is good (Neitz et al., 1989), and kennels with
clear sight lines out of the dog’s enclosure are beneficial in
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providing them with the ability to predict events and exert a
degree of control. Windows can be useful in providing such
sightlines, and structures, such as platforms, provide additional complexity.
Other areas for future research identified by the Joint Working
Group were:
–	The relationship between welfare and the physical and social
environment
–	Economical and practical ways of enriching the kennel
–	The relationship between pen size, number of individuals
and behavior
– Ways to prevent and manage aggression
–	The demand for different toys and chews
– The influence of early experience on behavior in laboratory
Beagles
–	The psychological and physiological effects of transport
As for many species, many indicators of welfare can be taken
(behavioral, physiological) but these still have to be interpreted
and this can be difficult. When making so-called improvements
care has to be taken to ensure that real welfare improvements
have been made.
There are various national and international standards that
provide minimum standards for dog housing. In Europe there
is the Council of Europe Convention ETS 123 and European
Community Directive 2010/63/EU, which will be enacted on
January 1, 2013, and more internationally there are the Organization for Economic Co-operation and Development (OECD),
Tab. 4: Comparison of minimum space allowances for
medium sized dogs
Minimum space allowance by guidelines

m2

feet 2

1996 NRC Guide

1.1

12

2011 NRC Guide

1.1

12

1986 UK (1 or 2 animals)

4.5

48.4

2010 EU (1 or 2 animals)

4.0

43.1

the International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human
Use (ICH), the International Cooperation on Harmonization
of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) and the World Health Organization
(WHO).
AAALAC (Association for Assessment and Accreditation of
Laboratory Animal Care International), is an international organization which promotes animal welfare through an accreditation program. AAALAC grants accreditation if the applicant
meets or exceeds the standards set forth by the three following
references plus additional reference documents:
1. “8th Edition of the Guide for the Care and Use of Laboratory
Animals”, NRC (2011);
2. “Guide for the Care and Use of Agricultural Animals in Research and Teaching” (Ag Guide), FASS (2010);
3. “European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes”,
Council of Europe (ETS 123).
AAALAC’s international accreditation program is carried out
mainly by independent experts, who actively visit sites, provide
advice and recommendations, and award accreditation. Professional and continuous improvement of the animal care and use
program, based on re-visits occurring every three years for continued accreditation, helps to raise animal welfare standards in
daily practice. A retrospective analysis of AAALAC site visits
in Europe from 2003 to 2008 revealed that most frequently the
areas that needed improvement before accreditation could be
granted were in the animal environment and veterinary care, and
within these areas the subcategories “behavioral management,
structural and social environment” and “preventive medicine,
surveillance, diagnosis” were most prominent. Institutions that
apply for accreditation have to submit a program description
which typically has a volume of 100 pages or more, and host
the site visitors who perform an in-depth review of the animal
care and use program. Currently there are over 60 AAALACaccredited European institutions, the majority pharmaceutical

Tab. 5: Stress indicators in dogs
Indicators of acute stress

Indicators of chronic stress

Low posture

Low posture

Body shaking

Increased autogrooming

Crouching

Paw lifting

Oral behaviors (tongue out, licking muzzle, swallowing)

Vocalizing

Restlessness

Repetitive behavior

Yawning

Coprophagy

Heart rate change

high cortisol/creatinine ratio

Increased cortisol/creatinine ratio

increased catecholamines

Peripheral leukocytosis

When stimulated:
High levels of locomotor activity
Increased levels of change of active state
Body shaking
Yawning
Ambivalent postures
Displacement behavior
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companies and contract research organizations (CROs), though
also academic and other institutions, participate in the accreditation program. In selecting a CRO, AAALAC-accreditation is an
important quality marker for animal welfare.
12 Discussion and suggestions

As the workshop participants had backgrounds from pharmaceutical and pesticide industries, CROs, the regulatory arena, animal
welfare organizations and academia, different views and experiences were brought into the discussion, and some opinions were
controversial. Nevertheless, trying to find a way toward consensus gave rise to many ideas, which are summarized here. Each
individual participant does not necessarily back each idea.
It was agreed that this workshop is evidence that industry and
animal welfare groups can work together towards achieving
best practices and furthering the 3Rs concept. This depends on
building trust and confidence, which are considered essential
if ideas and data are to be shared. The power of a consortium
consisting of various groups from different backgrounds to influence legislation and regulators is synergistic, and the value
of sharing information is priceless. This is the way considered
best to affect a change in ensuring harmonized best practice and
animal welfare issues in the future.
Unfortunately, methods to fully replace the use of dogs and
other animals are not available yet for some areas of research
and safety testing. It is therefore obviously desirable to develop
replacement methods and meanwhile reduce the numbers of
dogs used in experiments. It is not more ethical to substitute
dogs with another equally sentient species, e.g., mini-pigs.
Therefore, an important task is to further reduce dog use and optimize laboratory conditions by refinement approaches. In order
to further the refinement of work with laboratory dogs and other
animals, CAAT announced the creation of an Industry Refinement Working Group and preparatory discussions so far include
twelve companies. A grant from the Klingenstein Foundation
allows CAAT to serve as the secretariat for this initiative, which
may help to give the suggestions and recommendations from
this workshop a direct impact and follow-up.
12.1 Replacement

The Replacement of experiments on animals, including dogs, is
the final goal in both research and testing. Therefore, a key point
of action will be the identification and development of suitable
Replacement methods from areas like computer modeling techniques, in vitro methods, cell culture and tissue engineering that
will also be fit for international acceptance and could be integrated in testing strategies, test guidelines and data requirements
or that can be widely used in biomedical research. Extensive
funding will be needed and should be made available. Data-bases
should be created using a weight of evidence approach that also
includes a cost-benefit analysis and ethical reviews.
Furthermore, a working group should be formed to identify
more opportunities to conduct retrospective studies, in order to
determine the initial value of the experiment, the read-out, and
the practical benefit for humans. The point was made that closer
Altex 28, 4/11
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analysis of what results are actually used for regulatory decisions
can guide to develop selective assays. As an example (not involving dogs), a retrospective analysis of reproductive toxicity studies
was mentioned, where the outcome showed, that in 80% of the
cases testis toxicity was the reason for classification (Bremer et
al., 2007). This is already assessed in general toxicity repeat-dose
studies and is easier to model in vitro than the whole reproductive
cycle. Another retrospective study on neurovirulence testing in
monkeys showed that the test was unable to discriminate between
the attenuated, safe vaccine virus and virulent wild type strains
and was therefore banned (IABS, 2005).
A suggestion from the animal welfare side was to use the
“blank paper” approach: given the assumption that no suitable
test exists and toxicity studies would be developed de novo without historical prejudices, using newest technologies, and taking
into account the state-of-the-art knowledge without considering
existing liability issues or regulatory requirements. Such an activity would require an intense literature research for evidencebased information, including data from pharmaceutical industry,
and might lead to a whole new set of in vitro approaches.
12.2 Reduction

In the area of reduction clear statements were made, mainly by
the pharmaceutical industry based on their experience, which
every experimenter, study director or managing team should
follow. A guidance document might be useful that includes the
following points:
– Plan properly and upon demand (most drugs do not make it
into clinical trials).
– Avoid in vivo screening and parallel testing as much as possible, which requires the management to be on board.
– Choose species case-by-case, not based on preceding choice,
costs or availability.
– Mini-optimize early studies (1 sex, N=1/sex; short).
– Use fewer animals per project by combining studies and using interim sampling or biopsies.
– Avoid control animals whenever possible (e.g., in reversibility group).
– Challenge the need for reversibility data in studies, as reversibility does not distinguish adverse from non-adverse effects.
– Consider integrated approaches whenever possible, e.g., include safety pharmacology parameters in general toxicology
to prevent the need for additional repeat-dose studies.
– Start at young age of animals to cover potential juvenile issues and waive stand-alone juvenile studies whenever appropriate.
– Use the animals in multiple studies, e.g., in MTD studies
with insignificant toxicity.
–	Think globally by performing GLP studies with globally acceptable design in order to prevent any need for repetition.
–	Exchange data within industry, e.g., experience with species selection, excipients and findings irrelevant to humans
(“false positive compounds”).
– Use state-of-the-art methods to gain as much valuable data as
possible with a minimum of stress, e.g., wireless data collection systems.
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– Publish and educate.
– Share control groups for parallel running studies, encourage
CROs to do so as well. Sponsors can easily share control data.
– Do not try to save money by outsourcing into uncontrollable
environments.
Summarizing the above mentioned points and developing a best
practice guidance document would be a starting point for the
above mentioned Industry Refinement Working Group.

cal and there should be a minimum requirement for educational
training as well as assessment of the competence of animal caretakers, experimenters and their trainers, as described in the new
Directive 2010/63/EU.
An area where information is still needed, and which could
be addressed by additional workshops, is the requirement for
juvenile testing, because this may create a whole new point of
view on the need of animal testing.

12.3 Refinement of husbandry and care taking

12.5 Regulatory acceptance and globalization

Given the existing knowledge and an international accreditation
body some improvements in the area of refinement already have
been achieved but the main question remains: How should we
define animal welfare, what should be the minimum standards,
and how can we successfully measure applied animal welfare?
It was agreed that more information is needed and observational studies assessing laboratory animals in general should be
carried out, taking into consideration the different stages of their
life, starting with the breeding conditions, their socialization,
needs when kept in stock, and their behavior under experimental conditions leading to an “Animal Welfare best practice document”. This study should include state-of-the-art approaches
such as monitoring by video-surveillance, and offering the animal preferences to understand what it really needs.
This can be done by a step-by-step or a gap analysis but should
definitely lead to an evidence-based refinement approach. The
creation of an animal welfare score, similar to the trauma score
assessed in emergency settings in hospitals, was suggested.
The animal welfare score could be like a checklist of different
measures, with the distinct purpose of leading to a profile of a
balanced or at least un-distressed animal when following the
minimum recommendations.
12.4 Refinement of procedures

The workshop participants also identified a need to take action
regarding the severity of procedures. As discussed before, no
publicly available data describes commonly used procedures. A
study should be financed and conducted to identify severe procedures as defined in the severity classification in Annex VIII
of Directive 2010/63/EU14 and experts should confer to make
recommendations that would lessen their severity.
Humane endpoints need to be better defined; especially the
termination criteria in the maximum tolerated dose study, which
can inflict a severe level of distress and pain. Working groups
currently exist, e.g., EFPIA/NC3Rs acute toxicity project, which
could be encouraged to address this topic, taking into consideration the OECD Guidance Document 1915 on the recognition,
assessment and use of clinical signs as humane endpoints for
experimental animals used in safety evaluation.
The use of non-invasive methodologies, like PET scan imaging, as well as interim sampling, biomarker studies, biopsies
instead of killing, are preferred.
Well-trained, empathetic staff is one of the most important assets for animal welfare; therefore, training procedures are criti-

Regulatory acceptance and globalization are major factors
to take into account. As long as one market requests a certain
study, this type of test still will be carried out as seen in the
case of the one year study for pesticides, which has been abandoned by the EU and US, but is still required in Brazil and Japan. A formal meeting with regulators from different countries
is being discussed by CAAT-US, at which existing data can be
presented and decisions to adopt international standards can be
discussed.
Harmonization of minimum standards and data requirements
and adaptation to scientific and technical progress at a national
and international level is considered essential. This should be
done in Europe through the European Commission and more
internationally through the respective organizations, like the
OECD, the ICH and the VICH.
Furthermore it was recognized that regulatory authorities are
starting to be more confident in the quality of non-clinical data
and more flexible in considering non-standard approaches. New
experimental models including the use of novel tools are now
more readily accepted by regulatory authorities.
13 Recommendations

Increase knowledge
1. Observational studies to understand natural and kenneled behavior of dogs using preference and choice tests taking into
consideration the different stages of their life
2. Identification of the possibilities for retrospective studies, to
determine the initial value of the experiment, the read-out
and the practical benefit for the human
3. Given the lack of data assessing the predictive power from
dog to humans for a large number of drugs or drug candidates, a large retrospective analysis should be carried out
4. Individual identification of severe procedures performed
with laboratory animals with the goal to change them into
mild procedures
Guidance documents
1. Replacement guidance document
2. Reduction guidance document
3. “Animal Welfare best practice document” achieved by an
evidence-based approach creating an animal welfare score or
indicator

14 http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:En:PDF
15 http://www.imm.ki.se/sft/pdf/OECD19.pdf

338

r-altex_2011_4_326_340_Hasiwa.indd 338

Altex 28, 4/11

24.11.2011 19:56:11 Uhr

Hasiwa et al.

4. Minimum requirement for educational training and the ability to assess the competence of animal caretakers, experimenters and their trainers
5. Species selection guidance (currently under revision by EFPIA)
Online databases
1. Data sharing within the pesticide, chemical and pharmaceutical sectors
2.	Extension of the existing database of animal experiments
containing in vivo toxicological information on e.g., vehicles, solvents, excipients, preservatives, procedures, species
and selected chemicals including also a cost benefit analysis
and ethical reviews
Workshops and meetings
1. Juvenile testing requirement especially for dogs
2. Meetings for regulators to enhance global harmonization
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